Literature DB >> 21983488

Evidence for alteration of calpain/calpastatin system in PBMC of cystic fibrosis patients.

Monica Averna1, Roberto Stifanese, Roberta De Tullio, Laura Minicucci, Federico Cresta, Serena Palena, Franca Salamino, Sandro Pontremoli, Edon Melloni.   

Abstract

We are here reporting that in peripheral blood mononuclear cells (PBMC) of patients homozygous for F508del-CFTR the calpain-calpastatin system undergoes a profound alteration. In fact, calpain basal activity, almost undetectable in control PBMC, becomes measurable at a significant extent in cells from cystic fibrosis (CF) patients, also due to a 40-60% decrease in both calpastatin protein and inhibitory activity. Constitutive protease activation in CF patients' cells induces a large accumulation of the mutated cystic fibrosis transmembrane conductance regulator (CFTR) in the 100kD+70kD split forms as well as a degradation of proteins associated to the CFTR complex. Specifically, the scaffolding protein Na(+)/H(+) exchanger 3 regulatory factor-1 (NHERF-1) is converted in two distinct fragments showing masses of 35kD and 20kD, being however the latter form the most represented one, thereby indicating that in CF-PBMC the CFTR complex undergoes a large disorganization. In conclusion, our observations are providing new information on the role of calpain in the regulation of plasma membrane ion conductance and provide additional evidence on the transition of this protease activity from a physiological to a pathological function.
Copyright © 2011 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21983488     DOI: 10.1016/j.bbadis.2011.09.013

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  7 in total

1.  Inhibition of calpain 1 restores plasma membrane stability to pharmacologically rescued Phe508del-CFTR variant.

Authors:  Ana M Matos; Francisco R Pinto; Patrícia Barros; Margarida D Amaral; Rainer Pepperkok; Paulo Matos
Journal:  J Biol Chem       Date:  2019-07-19       Impact factor: 5.157

2.  The Functional Difference of Dendritic Cells in HBeAg Negative Chronic Hepatitis B Patients with Three Different Spleen Deficiency Syndromes and the Therapeutic Evaluation of Chinese Medicine Intervention Based on Syndrome Differentiation.

Authors:  Lei Wang; Li Zhang; Xiaoxia Feng; Lianjun Xing; Wei Zhang; Kaiping Jiang; Haiyan Song; Guang Ji
Journal:  Evid Based Complement Alternat Med       Date:  2014-06-29       Impact factor: 2.629

3.  Neutrophil Membrane Cholesterol Content is a Key Factor in Cystic Fibrosis Lung Disease.

Authors:  Michelle M White; Patrick Geraghty; Elaine Hayes; Stephen Cox; William Leitch; Bader Alfawaz; Gillian M Lavelle; Oliver J McElvaney; Ryan Flannery; Joanne Keenan; Paula Meleady; Michael Henry; Martin Clynes; Cedric Gunaratnam; Noel G McElvaney; Emer P Reeves
Journal:  EBioMedicine       Date:  2017-08-16       Impact factor: 8.143

4.  Dual roles of calpain in facilitating Coxsackievirus B3 replication and prompting inflammation in acute myocarditis.

Authors:  Minghui Li; Yangang Su; Yong Yu; Ying Yu; Xinggang Wang; Yunzeng Zou; Junbo Ge; Ruizhen Chen
Journal:  Int J Cardiol       Date:  2016-07-09       Impact factor: 4.164

Review 5.  Proteases, Mucus, and Mucosal Immunity in Chronic Lung Disease.

Authors:  Michael C McKelvey; Ryan Brown; Sinéad Ryan; Marcus A Mall; Sinéad Weldon; Clifford C Taggart
Journal:  Int J Mol Sci       Date:  2021-05-09       Impact factor: 5.923

6.  Calpain inhibition promotes the rescue of F(508)del-CFTR in PBMC from cystic fibrosis patients.

Authors:  Monica Averna; Marco Pedrazzi; Laura Minicucci; Roberta De Tullio; Federico Cresta; Franca Salamino; Sandro Pontremoli; Edon Melloni
Journal:  PLoS One       Date:  2013-06-13       Impact factor: 3.240

Review 7.  Proteomics and Metabolomics for Cystic Fibrosis Research.

Authors:  Nara Liessi; Nicoletta Pedemonte; Andrea Armirotti; Clarissa Braccia
Journal:  Int J Mol Sci       Date:  2020-07-30       Impact factor: 5.923

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.